Igniting
a Therapeutic
Butterfly Effect
for Kidney
Health
a Therapeutic
Butterfly Effect
for Kidney
Health
Igniting a Therapeutic
Butterfly Effect
for Kidney Health
Butterfly Effect
for Kidney Health
BUILDING THE FUTURE
FOR KIDNEY HEALTH
FOR KIDNEY HEALTH
LiveKidney is a clinical-stage company developing regenerative medicine for kidney diseases, aiming to improve the health and quality of life for kidney patients globally. The company’s products are based on proprietary, hydrogel-based formulations of mesenchymal stromal cells that facilitate the continuous release of bioactive compounds, demonstrating systemic and local effects via unique routes of administration. The company’s products modulate the immune system, reduce inflammation and fibrosis and restore mitochondrial function, thereby improving kidney function.
UNMET MEDICAL NEED IN KIDNEY DISEASE
In kidney disease, renal function is progressively damaged, reducing the kidney’s ability to filter toxins from the body. Current available treatments are insufficient, mostly addressing the patients’ symptoms and even with new therapies, patients still lose kidney function. About 30% of kidney disease patients eventually progress to renal failure, requiring dialysis (an 80 year old technology) or kidney transplant.
OUR TECHNOLOGY
LiveKidney is developing a novel cell therapy approach based on our proprietary cell-shielding, hydrogel delivery platform of mesenchymal stromal cells and novel routes of administration. Our proprietary platform is off-the-shelf, highly scalable, and cost effective.
OUR PIPELINE
Our lead product candidate, LK-01, is administered into the subcutaneous (SC) tissue and intended to treat autoimmune related kidney disease, including lupus nephritis (LN), IgA nephropathy, rheumatoid arthritis and systemic sclerosis. Our next-generation product candidate LK-02, is administered into the perirenal fat tissue (PRAT) and intended to improve kidney function for patients with metabolic syndrome.
| Product candidate Route of administration |
Kidney disease indication(s) | In vitro studies | Animal studies | Clinical studies |
|---|---|---|---|---|
| LK-01 (SC; US, IL) | Autoimmune disease (i.e. LN) | |||
| LK-02 (PRAT; IL) | Metabolic syndrome | |||
| In vitro studies |
➤ | Animal studies |
➤ | Clinical studies |
LK-01 (SC; US, IL)
Autoimmune disease (i.e. LN)
LK-02 (PRAT; IL)
Metabolic syndrome
Autoimmune disease (i.e. LN)
LK-02 (PRAT; IL)
Metabolic syndrome
MARKET OPPORTUNITY
Kidney disease affects approximately 1 billion people globally, with annual spending on chronic kidney disease in the US, by Medicare alone, amounting to $135 billion in 2023.
Autoimmune kidney disease
Our initial lupus nephritis indication is targeting a $2 billion market, with future large indications such as IgA nephropathy and rheumatoid arthritis. Lupus nephritis occurs in 60% of lupus patients, predominantly affecting women of childbearing age, and is correlated with a higher mortality rate.
Kidney disease associated with metabolic syndrome
Metabolic syndrome is a cluster of diabetes, obesity, cardiovascular diseases, and fatty liver that is estimated to affect 1 in 3 adults in the US alone. It is associated with significantly increased risk of chronic kidney disease, reflecting an additional multi-billion-dollar market opportunity.
MANAGEMENT TEAM
Dr. Alon Yaar, DVM, MBA;
CEO
A serial entrepreneur and former CEO/COO of NeuroDerm (NASDAQ:NDRM); later acquired by Mitsubishi Tanabe in 2017
Roy Golan, CPA, LLM;
Finance Leader
Former CFO of NeuroDerm (NASDAQ:NDRM), later acquired by Mitsubishi Tanabe; former President & CFO of Exalenz Bioscience and CFO of Ayala Pharma
Dorit Sokolov, MBA, B. Pharm;
Business Leader
Longtime multi-disciplinary biotech investor and company builder with experience in innovation, venture creation, and business development
Dr. Masha Simanovsky, Ph.D.;
R&D Leader
Expert in cell therapy and extracellular vesicles
Dr. Shimon Amselem, Ph.D.;
Technology Leader
Expert in implantable biodegradable polymers; significant contributions to five FDA approvals and four INDs in Phase II/III
Dr. Nadya Lisovoder, MD;
Clinical Leader
Clinical adviser with vast experience in clinical studies in the pharma industry
Miri Sani;
Regulatory Affairs Leader
Expert in Regulatory Affairs; led FDA, EMA, and CE mark approvals in diverse fields
ADVISORY BOARD
Prof. Chaim Putterman
Professor of Medicine & Immunology at the Albert Einstein College of Medicine
Prof. Lilach O. Lerman
Professor of Medicine at The Renovascular Disease Research Laboratory, Mayo Clinic
Prof. Gary Gilkeson
Professor of Medicine, Associate Dean for Faculty Affairs and Faculty Development, Medical University of South Carolina
Dr. Shimon Aronhime
Lecturer, Department of Interventional Radiology, Shamir Medical Center, Tel Aviv University
Eli Gelman
Chairman of the Board, Amdocs Limited, Chairman of the Executive Council of Tel Aviv University
Jonathan Leitersdorf
Angel investor and architect developer in the US, Spain and Switzerland;
Following his brother’s fatal chronic kidney disease, initiated cell-based research to find a cure for this global epidemic and later founded Livekidney
Following his brother’s fatal chronic kidney disease, initiated cell-based research to find a cure for this global epidemic and later founded Livekidney
CONTACT
